Management of Old Myocardial Infarction

Core Pharmacological Management

• The European Society of Cardiology recommends that all patients with a history of old MI must be on indefinite aspirin 75-162 mg daily, a beta-blocker, an ACE inhibitor (or ARB if intolerant), and high-intensity statin therapy, as this is the non-negotiable foundation of secondary prevention that reduces mortality and recurrent events 1, 2, 3.
• Aspirin 75-162 mg daily must be continued indefinitely in all post-MI patients, reducing vascular events by 36 per 1000 patients treated over 27 months, according to the American College of Cardiology 1, 3.
• The American Heart Association recommends that if true aspirin allergy exists, substitute clopidogrel 75 mg daily as the best alternative 3.
• Dual antiplatelet therapy (aspirin plus clopidogrel, ticagrelor, or prasugrel) should have been continued for 12 months post-MI if a stent was placed, as suggested by the European Heart Journal 1.
• The American College of Cardiology advises to never use ibuprofen—it blocks aspirin's antiplatelet effects 3.
• Beta-blockers must be continued indefinitely after MI, as they improve prognosis and reduce mortality, according to the European Heart Journal 1, 2, 3.
• The American Heart Association recommends that ACE inhibitors reduce the risk of death and major cardiovascular events even when initiated months or years after MI 2.
• High-intensity statin therapy (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) must be initiated without delay with a target LDL-C <1.8 mmol/L (70 mg/dL), as recommended by the European Heart Journal 1, 5, 6.

Risk Factor Modification

• The American College of Cardiology states that smoking cessation is mandatory—this is not negotiable, and provide counseling to both patient and family, combined with pharmacological therapy including nicotine replacement, varenicline, or bupropion 3, 4.
• Hypertension and hyperlipidemia must be treated vigorously because the benefits are particularly marked in patients with prior MI, according to the American Heart Association 2.
• The European Society of Cardiology recommends implementing a Mediterranean-type diet low in saturated fat, high in polyunsaturated fat, and rich in fruits and vegetables 6.

Cardiac Rehabilitation

• Enrollment in a structured cardiac rehabilitation program is a Class I recommendation that directly addresses mortality and functional recovery, as suggested by the American College of Cardiology 5, 6.
• Cardiac rehabilitation reduces cardiovascular mortality by 33%, non-fatal MI by 36%, and stroke by 32% when extended beyond standard 6-12 weeks, according to the American Heart Association 6.

Assessment of Cardiac Function

• Echocardiography should be performed to assess LV and RV function, detect mechanical complications, and exclude LV thrombus, as recommended by the European Society of Cardiology 4, 6.
• Patients with LVEF 31-40% or lower require Holter monitoring for possible ICD consideration, according to the American College of Cardiology 6.

Anticoagulation Considerations

• Warfarin (INR 2.0-3.0) is indicated for patients with persistent or paroxysmal atrial fibrillation, as suggested by the American Heart Association 4.
• Warfarin may be considered as an alternative to clopidogrel in patients <75 years with true aspirin allergy who are at low bleeding risk and can be monitored adequately (target INR 2.5-3.5), according to the American College of Cardiology 3.

Monitoring and Follow-Up

• Schedule an early follow-up visit within 2-4 weeks to assess symptoms, medication tolerance, and titration needs, as recommended by the American College of Cardiology 6.
• Review the medication list and uptitrate ACE inhibitors, beta-blockers, and statins toward target doses, according to the American Heart Association 6.
• Screen systematically for depression during hospitalization and monthly for the first year—treat with combined cognitive-behavioral therapy plus selective serotonin reuptake inhibitors when identified, as suggested by the American College of Cardiology 6.

Common Pitfalls to Avoid

• Do not discontinue beta-blockers or ACE inhibitors prematurely—these medications provide long-term mortality benefit even years after MI, according to the American Heart Association 2.
• Avoid calcium channel blockers with negative inotropic effects (verapamil, diltiazem) in patients with reduced LVEF, as they may be harmful, as recommended by the American College of Cardiology 2.